Male breast cancer: two cases with objective regressions from calusterone (7 alpha, 17 beta-dimethyltestosterone) after failure of orchiectomy.
Calusterone (7 alpha, 17beta-dimethyltestosterone) is an orally effective weakly androgenic steroid. The antitumor efficacy of calusterone, 200 mg per day against objectively progressing advanced breast cancer in females has already been reported. In the present study calusterone was used in metastatic breast cancer in two male patients. Both had failed to continue respond to orchiectomy and had measurable lesions one in the lungs, the other in the bones. Both patients showed objective regression (blastic response of osteolytic lesions and disappearance of lung metastases) lasting five months in one patients and more than seven months in the other, who is still in regression. Further experience is necessary for statistically adequate results.
D000231:Adenocarcinoma, Papillary / Q000188:drug therapy* / Q000601:surgery; D000368:Aged; D001365:Axilla; D001859:Bone Neoplasms / Q000188:drug therapy; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000188:drug therapy* / Q000601:surgery; D002369:Castration; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008207:Lymphatic Metastasis; D008297:Male; D008408:Mastectomy; D008777:Methyltestosterone / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012075:Remission, Spontaneous
D008777:Methyltestosterone